UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ |
Preliminary Proxy Statement |
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ |
Definitive Proxy Statement |
☐ |
Definitive Additional Materials |
☒ |
Soliciting Material Pursuant to §240.14a-12 |
MASIMO CORPORATION
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)
Payment of Filing Fee (Check the appropriate box): |
|
☒ |
No fee required. |
☐ |
Fee paid previously with preliminary materials. |
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
Persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently valid OMB control number.
On May 31, 2024, Masimo Corporation issued the following press release:
Masimo Announces Nomination of Independent
Candidate to the Board of Directors
Experienced Medical Device Executive Christopher
Chavez to Stand for Election at 2024 Annual Meeting
Company Extends Third Settlement Offer to Politan;
Politan Again Rejects Offer
IRVINE, Calif. – May 31,
2024 – Masimo (NASDAQ: MASI) announced today that its Board of Directors has nominated Christopher Chavez for election as a Class
II Director at the Company’s 2024 Annual Meeting of Stockholders. Following Rolf Classon’s unexpected resignation from the
Board on May 10, 2024, due to health issues, members of the Board contacted and considered several candidates with skills and experiences
that would enhance the Board’s slate. Mr. Chavez brings more than 30 years of leadership experience in the medical device industry,
including two past appointments as a public company CEO and many years as an independent public company director.
Craig Reynolds, Masimo’s Lead Independent Director and Chair
of the Nominating, Compliance and Corporate Governance Committee, said, “We’re pleased to announce Chris’s nomination.
With his successful track record as a former CEO at two medical technology companies, the industry expertise he demonstrated in his role
as the Chair of the Medical Device Manufacturers Association and his experience as an independent public company director, Mr. Chavez
would add valuable strategic, operational and transactional expertise to the Masimo Board.”
“I am excited about the prospect of joining Masimo’s Board
and helping the Company continue on its growth trajectory,” said Mr. Chavez. “I look forward to working with the entire Board
to help Masimo reach its full potential.”
Separately, the Company extended its third settlement offer to Politan
Capital Management, proposing that Mr. Chavez and Politan nominee William Jellison be added to the Board. The expansion of the Board to
seven members, six of whom are independent, would avoid concerns of potential deadlock on the Board. Politan rejected the offer.
Mr. Chavez was most recently Chairman, Chief Executive Officer and
President of TriVascular, Inc., where, over the course of four years, he led the company’s commercialization of an innovative abdominal
aortic stent graft system, including achieving FDA premarket approval, and successfully negotiated the merger of TriVascular into Endologix,
Inc. in 2016.
Prior to TriVascular, Mr. Chavez served as CEO and President of Advanced
Neuromodulation Systems, Inc. (ANSI), where he led the company’s growth from a $50 million market capitalization in 1997 to $1.4
billion in 2005, when he negotiated the sale of ANSI to St. Jude Medical. Following the acquisition, Mr. Chavez served as President of
St. Jude Medical’s Neuromodulation Division until 2011.
Prior to ANSI, Mr. Chavez spent 15 years at Johnson & Johnson,
most recently as Vice President and General Manager of the Worldwide Infection Prevention Business.
In addition to his board service at ANSI
and TriVascular, Mr. Chavez previously served as an independent director at Endologix, Nuvectra Corp. and Advanced Medical Optics Inc.,
which was acquired by Abbott Laboratories in 2009. He also served as Chair of the Medical Device Manufacturers Association and Chairman
of the Dallas/Fort Worth Health Industry Council. Mr. Chavez received his MBA from the Harvard Business School and holds a bachelor’s
degree in accounting from New Mexico State University.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in connection
with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding
the 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) of Masimo and the potential stockholder approval of the
Board’s nominees. These forward-looking statements are based on current expectations about future events affecting Masimo and are
subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Masimo’s control and could
cause its actual results to differ materially and adversely from those expressed in its forward-looking statements as a result of various
risk factors, including, but not limited to (i) uncertainties regarding a potential separation of Masimo’s Consumer Business, (ii)
uncertainties regarding future actions that may be taken by Politan in furtherance of its nomination of director candidates for election
at the 2024 Annual Meeting, (iii) the potential cost and management distraction attendant to Politan’s nomination of director nominees
at the 2024 Annual Meeting and (iv) factors discussed in the “Risk Factors” section of Masimo’s most recent reports
filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov.
Although Masimo believes that the expectations reflected in its forward-looking statements are reasonable, the Company does not know whether
its expectations will prove correct. All forward-looking statements included in this communication are expressly qualified in their entirety
by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak
only as of today’s date. Masimo does not undertake any obligation to update, amend or clarify these statements or the “Risk
Factors” contained in the Company’s most recent reports filed with the SEC, whether as a result of new information, future
events or otherwise, except as may be required under the applicable securities laws.
Additional Information Regarding the 2024 Annual Meeting of Stockholders
and Where to Find It
The Company has filed a preliminary
proxy statement and draft form of GOLD proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection
with its solicitation of proxies for its 2024 Annual Meeting. The proxy statement is in preliminary form and the Company intends to file
and mail a definitive proxy statement to its stockholders. THE COMPANY’S STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE
PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING GOLD PROXY CARD WHEN THEY BECOME AVAILABLE AS THEY WILL
CONTAIN IMPORTANT INFORMATION. Stockholders may obtain the proxy statement, any amendments or supplements to the proxy statement and other
documents as and when filed by the Company with the SEC without charge from the SEC’s website at www.sec.gov.
Certain Information Regarding Participants
The Company, its directors
and certain of its executive officers and employees may be deemed to be participants in connection with the solicitation of proxies
from the Company’s stockholders in connection with the matters to be considered at the 2024 Annual Meeting. Information
regarding the direct and indirect interests, by security holdings or otherwise, of the Company’s directors and executive
officers in the Company is included in Amendment No. 1 to the Company’s Annual Report on Form 10-K for the fiscal year ended
December 30, 2023 under the heading “Security Ownership of Certain Beneficial Owners and Management”, filed with the SEC
on April 29, 2024, which can be found through the SEC’s website at
https://www.sec.gov/ix?doc=/Archives/edgar/data/937556/000093755624000027/masi-20231230.htm and in the Company’s preliminary
proxy statement for the 2024 Annual Meeting, which was filed with the SEC on May 31, 2024, and will be included in the
Company’s definitive proxy statement for the 2024 Annual Meeting, once available. Changes to the direct or indirect interests
of Masimo’s securities by directors and executive officers are set forth in SEC filings on Statements of Change in Ownership
on Form 4 filed with the SEC on April 30, 2024 and May 3, 2024, which can be found through the SEC’s website at
https://www.sec.gov/Archives/edgar/data/937556/000093755624000030/xslF345X05/wk-form4_1714522261.xml and
https://www.sec.gov/Archives/edgar/data/937556/000093755624000032/xslF345X05/wk-form4_1714772837.xml, respectively. More detailed
and updated information regarding the identity of these potential participants, and their direct or indirect interests of the
Company, by security holdings or otherwise, will be set forth in the proxy statement for the 2024 Annual Meeting and other materials
to be filed with the SEC. These documents, when filed, can be obtained free of charge from the sources indicated above.
# # #
Investor Contact: Eli Kammerman |
Media Contact: Evan Lamb |
(949) 297-7077 |
(949) 396-3376 |
ekammerman@masimo.com |
elamb@masimo.com |
2
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Jul 2023 to Jul 2024